We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

Advanced Biological Releases First Commercial CE-IVD Registered COVID-19 rRT-PCR Assay Also Validated for Saliva

By LabMedica International staff writers
Posted on 08 Jul 2020
Print article
Image: qRT-PCR Workflow (Photo courtesy of Advanced Biological Laboratories)
Image: qRT-PCR Workflow (Photo courtesy of Advanced Biological Laboratories)
Advanced Biological Laboratories (ABL Luxembourg) has announced the CE-IVD marking of its UltraGene Combo2Screen SARS-CoV-2 qPCR assay.

The UltraGene Combo2Screen SARS-CoV-2 qPCR assay is the first qPCR detection kit now validated with SARS-CoV-2 RNA extracted from nasopharyngeal swabs and saliva. The collection of saliva samples is not invasive and allows easier and broader population testing and screening. This optimization consisting in using saliva specimen as an input material for the SARS CoV-2 RNA extraction and qPCR detection, rather than traditional nasopharyngeal swabs, helps in improving the workflow, costs and convenience of the test together with the comfort of the patients. It allows targeting of asymptomatic patients, increasing acceptance of patients for testing and reducing workload and risk of infection for healthcare professionals performing nasopharyngeal or oropharyngeal collections. Patients collect saliva samples under the supervision of healthcare professionals under a simpler and painless collection protocol.

The UltraGene Combo2Screen CE-IVD assay targets two highly conserved regions of the SARS-CoV-2 genome (Nucleocapsid (N) and Envelop (E) genes) in a multiplex format which includes an internal control. The test remains one of the most sensitive and easy to use assays from the market (~200 cp/mL), either with naso-oropharyngeal or saliva samples. It is compatible with most of the automated or manual RNA extraction methods, as well as with most of the qPCR instruments.

“We are proud to enhance our COVID-19 line of solutions. Converting the assay into a non-invasive fluid saliva collection workflow should significantly help increasing the number of people being tested and ease the access to diagnostics to fragile population such as children or elderly patients and to asymptomatic patients” said Dr. Chalom Sayada, CEO of ABL. “Proactive saliva collection strategy at schools and business places shall be foreseen to monitor prospectively SARS-CoV-2 infection”

Related Links:
Advanced Biological Laboratories

Print article


Molecular Diagnostics

view channel
Image: Micrograph of gold nanostar biosensors used to detect cancer-related microRNAs (Photo courtesy of Duke University School of Engineering)

Nanostar Biosensors Use Raman Scattering for Direct Detection of Cancer-Related MicroRNAs

A novel non-invasive nanoparticle-based assay detects cancer-related microRNAs without use of labels or target amplification. MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.